Interview with Mark Fladrich, Managing Director, Australia & New Zealand,…
You returned to Australia a year ago after spending eight years in Europe with the company. In your view, what were the key changes in the Australian market? Looking at…
Address: 5 Alma Road, North Ryde NSW 2113,Australia
Tel: +61 2 9978 3500
Web: http://www.astrazeneca.com.au/home/
AstraZeneca Australia is engaged in the research, development, manufacture and supply of medicines that aim to make a real difference to the lives of Australians.
AstraZeneca is one of Australia’s largest private sector investors in medical research and development (R&D) and has, invested more than $250 million in Australia in the last decade.
It is the largest national manufacturer of pharmaceuticals in Australia, providing $1.2 billion of medicines to the local market and $200 million in exports.
AstraZeneca currently involved in more than 50 clinical trials at over 200 sites across Australia, investigating potential new treatments in the areas of oncology, cardiovascular, diabetes, infection, gastrointestinal, neuroscience, respiratory, and inflammation.
The company employs more than 900 people in Australia and is committed to being recognised as an ‘Employer of Choice’.
AstraZeneca couples a global reach with local knowledge that stems from its long heritage in Australia that dates back to 1957.
AstraZeneca focuses on the following health care areas: cardiovascular, diabetes, gastrointestinal, neuroscience, oncology, respiratory, anaesthesia and pain management.
You returned to Australia a year ago after spending eight years in Europe with the company. In your view, what were the key changes in the Australian market? Looking at…
In an exclusive new podcast, DIA Global Forum Australia/New Zealand Regional Editor Richard Day (University of New South Wales, Medicine, St. Vincent’s Hospital) and John Skeritt, Head of Australia’s Therapeutic Goods Administration (TGA),…
Janssen Australia & New Zealand’s Bruce Goodwin argues that greater adoption of patient-centric practices is beneficial to patients, companies and healthcare systems as a whole. Goodwin also gives his five…
Can you start by giving our readers a brief overview of the company’s history here and your most notable achievements? Initially the company was founded as a small distributor of…
Would you begin by outlining the role & importance of George Clinical within the George Institute, highlighting recent milestones & achievements? George Clinical is an important division of the Institute,…
Would you begin by giving an introduction to our international readers of the institute, highlighting recent milestones & achievements and the current focus areas of its research activities? Broadly speaking,…
For those that are not familiar with your name, would you start by introducing yourself? After obtaining my PhD in cardiovascular physiology I moved to Boston to work at MIT…
Rare Voices Australia is a new organisation that has been established after the national rare diseases symposium in 2011. Can you please begin with giving our readers an introduction to…
In some ways the Australian medicines industry is going through the same restructuring and challenges as the industry is going through globally: the country deals with patent cliffs, companies are…
Can you outline the significance of the current PBS to the industry and in particular the impact it has on service providers to the industry such as Hahn? As service…
Senior Partner Dr Sree Haran has also participated in this interview. TranScrip Partners is by now a well-established player in the UK but a new player in Asia Pacific. Would…
Speaking to the Australian environment, how would you rate the market in terms of companies like Swisse? After traveling the world, the Australian market has shown to be one of…
In our interviews we have been hearing two opinions on the success of PBS reforms: that it works as it should in providing space for innovative medicine listings, and that…
See our Cookie Privacy Policy Here
